ISPOR 4th Asia-Pacific Conference Released Presentations
 

RELEASED PRESENTATIONS
 

Please visit this page again as more presentations will be available soon.


PODIUM AND POSTER PRESENTATIONS

For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 15th Annual International Meeting, see: ISPOR Outcomes Research Digest an electronic database of over 13,500 research papers presented at ISPOR Annual International Meetings, ISPOR Annual European Congresses, and biennial ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Outcomes Research Digest:  http://www.ispor.org/research_study_digest/research_index.asp
  • Under Meeting select 4th Asia-Pacific Conference – Phuket, Thailand – 2010, then Search for all available research podium and poster abstracts and presentations from the meeting.  Alternatively search by disease/disorder, topic or subtopic

EDUCATIONAL SYMPOSIA

Meeting Payer and HTA Requirements: The Value of New Innovative Biologic Therapy in the Treatment of WAMD
(Sponsored by Novartis)

Moderator: Shanlian Hu MD, MSc, Professor, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China

CONSIDERATIONS FOR THE ECONOMIC EVALUATION OF NEW BIOLOGIC THERAPIES
Speaker: Shanlian Hu MD, MSc, Professor, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China

SPOTLIGHT ON NEOVASCULAR AMD: DISEASE BURDEN AND THERAPEUTIC OPTIONS
Speaker: Dr. Paisan Ruamviboonsuk, Department of Ophthalmology, Rajvavithi Hospital, Bangkok, Thailand

ANTI-VEGF THERAPY IN NEOVASCULAR AMD: COST-EFFECTIVENESS EVALUATION AND REVIEW OF EVIDENCE
Speaker: Alan Haycox PhD, Professor, University of Liverpool, Liverpool, UK


What Is The "Right" Cost Per QALY For Innovative And Life-Saving Oncology Or End-Of-Life Therapies?
(Sponsored by Pfizer)

Moderator: Shanlian Hu MD, MSc, Professor, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China

NICE END OF LIFE GUIDELINE AND ITS IMPLICATIONS
Kenneth KC Lee JP, MPhil, PhD, Professor of Pharmacy and Head of Pharmacy Program, School of Medicine and Health Sciences, Monash University, Kuala Lumpur, Malaysia

Global experience on ICER criteria application
Boxiong Tang PhD, Outcomes Research, Emerging Markets, Pfizer Inc, New York, NY, USA


HTA CHALLENGES IN ASIA: PROGRESS THROUGH PARTNERSHIPS
(Sponsored by Eli Lilly) 

Moderator: Bong-Min Yang PhD, Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea 

ENGAGING WITH STAKEHOLDERS IN THE HTA PROCESS: SOME OBSERVATIONS OF AUSTRALIAN EXPERIENCE
Speaker: Rosalie Viney PhD, Associate Professor of Health Economics and Deputy Director, Centre for Health Economics Research and Evaluation, Faculty of Business, University of Technology, Sydney, Australia 

THE NICE WAY OF INVOLVING STAKEHOLDERS
Speaker: Michael Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

STAKEHOLDERS PARTICIPATION IN THE HTA PROCESS: SOUTH KOREA
Speaker: Bong-Min Yang PhD, Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea

 


ISSUE PANELS

IP1: ISSUES IN DEVELOPING PHARMACOECONOMIC GUIDELINES IN ASIA

DEVELOPMENT OF PHARMACOECONOMIC GUIDELINES IN KOREA
Michael Drummond, Professor of Health Economics, Centre for Health Economics, University of York, York, UK


IP2: HEALTH ECONOMIC CONSIDERATIONS FOR PERSONALIZED MEDICINE IN ASIA: USING GENOMIC PROFILING TO GUIDE TREATMENT DECISIONS IN EARLY STAGE BREAST CANCER

EVALUATING GENOMIC ASSAYS IN ONCOLOGY: REFERENCE TO ONCOTYPE DX AS A CASE STUDY
Calvin Chao, MD, MBA, Director of Medical Affairs, Medical Affairs, Genomic Health, Inc., Redwood City, CA, USA

HEALTH ECONOMIC CONSIDERATIONS FOR PERSONALIZED MEDICINE IN ASIA: USING GENOMIC PROFILING TO GUIDE TREATMENT DECISIONS IN EARLY STAGE BREAST CANCER
Gilberto de Lima Lopes, MD, MBA, Assistant Director For Clinical Research, Johns Hopkins Singapore International Medical Centre, Johns Hopkins University, Singapore


IP3: HOW HIGH IS HIGH OF COST-EFFECTIVENESS THRESHOLD IN ASIA? VALUE JUDGMENT OF QALYS OR HOW MUCH CAN WE SPEND?

HOW HIGH IS HIGH OF COST-EFFECTIVENESS THRESHOLD IN ASIA? VALUE JUDGMENT OF QALYS OR HOW MUCH CAN WE SPEND?
Mingliang Zhang PhD, Senior Director, Worldwide Market Access, Global Strategic Marketing and Market Access, Johnson and Johnson Pharmaceutical Services, Raritan, NJ, USA

CURRENT PRACTICE OF USING ICER THRESHOLD IN ASIA: TAIWAN
Yen-Huei (Tony) Tarn PhD, MS, Executive Director, Center for Pharmaceutical Care Development, National Union of Pharmacist Association, Taipei, Taiwan


IP4: RISK-SHARING SCHEMES IN THE ASIAN MARKETPLACE: WHAT ARE THE STEPS FOR SUCCESS?

RISK-SHARING SCHEMES IN THE ASIAN MARKETPLACE: WHAT ARE THE STEPS FOR SUCCESS?
Lisbet Coulton, Director, International Pricing & Reimbursement, United BioSource Corporation – Europe, London, UK

PERSPECTIVES ON RISK SHARING BASED ON A SURVEY IN THAILAND
Nathorn Chaiyakunapruk, PharmD, PhD, Associate Professor, Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Naresuan University, Muang, Phitsanulok, Thailand

INITIATIVE OF RISK SHARING SCHEMES IN CHINA
Wen Chen, PhD, Professor, Center for Pharmacoeconomic Research & Evaluation, Fudan University, Shanghai, China

RISK-SHARING SCHEMES IN THE ASIAN MARKETPLACE: WHAT ARE THE STEPS FOR SUCCESS?
Abdulkadir Keskinaslan, MD, MBA, MPH, Market Pricing Director Asia, Novartis Pharma AG, Basel Switzerland


IP5: STRENGTHENING HEALTH TECHNOLOGY ASSESSMENT CAPACITY IN DEVELOPING COUNTRIES: CONTRIBUTIONS OF INTERNATIONAL ORGANIZATIONS? 

STRENGTHENING HEALTH TECHNOLOGY ASSESSMENT CAPACITY IN DEVELOPING COUNTRIES: CONTRIBUTIONS OF INTERNATIONAL ORGANIZATIONS?
Yot Teerawattananon MD, PhD, Program Leader, Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand

Strengthening Pharmacoeconomics & Outcomes Research Capacity in Asia: ISPOR INITATIVES
Scott Ramsey PhD, MD, Member & Professor, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA

HTA International: The Global Network of Doers and Users of HTA
Laura Sampietro-Colom MD, PhD, President, Health Technology Assessment International (HTAi), Edmonton, AB, Canada

Strengthening Pharmacoeconomics and outcomes research capacity in developing countries: NICE International
Kalipso Chalkidou PhD, MD, Director - NICE International, National Institute for Health and Clinical Excellence, London, UK


IP6: DESIGNING CLINICAL TRIALS: THE CHALLENGES OF MEETING THE NEEDS OF PAYERS VS REGULATORS?

DESIGNING CLINICAL TRIALS: THE CHALLENGES OF MEETING THE NEEDS OF PAYERS VS REGULATORS: PERSPECTIVE OF A REGULATOR
Ruth Lopert, Principal Medical Adviser, Therapeutic Goods Administration, Canberra, Australia

DESIGNING CLINICAL TRIALS: THE CHALLENGES OF MEETING THE NEEDS OF PAYERS VS REGULATORS: THE PAYER PERSPECTIVE
Rosalie Viney PhD, Associate Professsor, Centre for Health Economics Research and Evaluation, University of Technology, Sydney, Broadway, NSW, Australia

DESIGNING CLINICAL TRIALS: THE CHALLENGES OF MEETING THE NEEDS OF PAYERS VS REGULATORS: A RESEARCH PERSPECTIVE
Michael Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK


IP7: APPLICATION OF ECONOMIC EVALUATION TOOLS FROM THE UNITED STATES AND EUROPE TOWARD PRICING AND REIMBURSEMENT STRATEGIES IN THE ASIA-PACIFIC REGION?

RESULTS FROM A SURVEY ON HOW ECONOMIC EVALUATION HAS BEEN INCORPORATED INTO FORMULARY DECISION MAKING IN THE UNITED STATES
Diana Brixner RPh, PhD, Professor and Chair, Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA

PRESENTATION OF RESULTS OF SURVEYING KEY GLOBAL MARKETS AS TO THEIR APPROACHES TO PRICING AND REIMBURSEMENT
Abdulkadir Keskinaslan MD, MBA, MPH, Market Pricing Director Asia, Novartis Pharma AG, Basel, Switzerland

DISCUSSION OF HOW ECONOMIC EVALUATION HAS BEEN USED IN KEY EUROPEAN COUNTRIES
Alan Haycox MA, PhD, Reader in Health Economics, University of Liverpool, Liverpool, UK


IP8:MANAGING COSTS AND QUALITY OF CARE IN OLDER ADULTS – A TALE OF 3 COUNTRIES?

MANAGING COSTS AND QUALITY OF CARE IN OLDER ADULTS – A TALE OF 3 COUNTRIES
Vithaya Kulsomboon PhD, Associate Dean/Associate Professor, Department of Social and Administrative Pharmacy, Chulalongkorn University, Bangkok, Thailand


IP9: PHARMACEUTICAL REIMBURSEMENT – TO RESTRICT OR NOT TO RESTRICT: LESSONS LEARNT FROM AUSTRALIAN EXPERIENCE?

HOW DO RESTRICTIONS HELP AND HINDER IN DECISION MAKING AND REIMBURSEMENT?
Rosalie Viney PhD, Associate Professor, Centre for Health Economics Research and Evaluation, University of Technology, Sydney, Broadway, NSW, Australia


WORKSHOP PRESENTATIONS

W8: THE NEW GERMAN METHODS FOR ECONOMIC EVALUATION AND THEIR APPLICABILITY IN ASIA
Discussion Leaders: J. Jaime Caro MD, Senior Vice President of Health Economics, United BioSource Corporation, Lexington, MA, USA; Charalabos-Markos Dintsios MPH, MA, Scientific Staff Department of Health Economics, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany; Anja Schwalm MSc, Health Economist, Health Economics, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany; Isao Kamae MD, DrPH, Professor of Pharmacoeconomics, JPMA Research and Education Project, Graduate School of Health Management, Keio University, Fujisawa-City, Kanagawa, Japan

4th Asia-Pacific Conference Main Page